<DOC>
	<DOC>NCT00627887</DOC>
	<brief_summary>The purpose of the study is to determine if continuation electroconvulsive therapy (ECT) is safe and effective in relapse prevention of depression.</brief_summary>
	<brief_title>Randomised Controlled Trial of Electroconvulsive Therapy (ECT) in Relapse Prevention of Depression</brief_title>
	<detailed_description>Randomized multicenter clinical trial with two parallel groups. Patients with major depression (unipolar or bipolar), who have remitted with electroconvulsive therapy (ECT) are eligible. All patients receive pharmacotherapy (venlafaxine target dose 300mg/day, and lithium target dose 0,5-0,8 mmol/L). The intervention is continuation unilateral ECT weekly for the first 6 weeks thereafter every 2 weeks for one year. Depressive relapse is the primary outcome measure.</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<mesh_term>Lithium Carbonate</mesh_term>
	<criteria>1. MINIPLUS verified major depressive episode (unipolar or bipolar). 2. ECT within the last 3 weeks. 3. Either Remission defined as MADRS &lt; 10 or 4. Response defined as MADRS &lt; 15 combined with patient assessed CGII of at least much improved 1. Schizophrenia or Schizoaffective disorder 2. Addiction or Dependence 3. Kidney disease that contraindicates lithium treatment 4. Vascular or heart disease that contraindicates venlafaxine treatment 5. Uncontrolled Epilepsia 6. Age less that 18 7. Pregnancy or Lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Depressive Disorder, Major</keyword>
	<keyword>Electroconvulsive Therapy</keyword>
	<keyword>Lithium Carbonate</keyword>
	<keyword>venlafaxine</keyword>
</DOC>